Navigation Links
Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
Date:12/7/2008

r the placebo group. The infusion of avidin was well- tolerated with no allergic reactions observed.

Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b ComparedWith Warfarin in Subjects With Non-Valvular Atrial Fibrillation

[Abstract #33]

Jeffrey I. Weitz, MD, HendersonResearch Centre, Hamilton, Canada

The primary objective of this study was to evaluate the safety of four dosing regimens of DU-176b in patients with non-valvular atrial fibrillation. This phase II study found that two regimens (30 mg and 60 mg once-daily) of an investigational oral Factor Xa inhibitor, DU-176b, are safe in patients with non-valvular atrial fibrillation, making the drug a potential substitute for warfarin, the conventional blood-thinning agent used in such patients to prevent stroke.

Dosing of warfarin is complicated because it interacts with many commonly-used medications and even certain foods. For that reason, patients receiving warfarin require regular blood testing to monitor the international normalized ratio (INR) to ensure that an adequate yet safe dose of warfarin is given.

A total of 1,146 patients with atrial fibrillation were randomized to receive either one of four fixed-dose regimens of DU-176b (30 mg once-daily, 30 mg twice-daily, 60 mg once-daily, 60 mg twice- daily) or warfarin (dose-adjusted to a target INR of 2.0 to 3.0) for 12 weeks. The primary endpoints of the study were the incidence of bleeding events (major and clinically relevant non-major) and elevated liver enzymes and/or bilirubin, which might be indicative of hepatic toxicity. Secondary endpoints included major adverse cardiovascular events, stroke, systemic embolism, acute myocardial infarction, hospitalizations due to
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... NEWTON, Mass. and JERUSALEM ... privately-held biopharma company developing octreotide capsules, its lead product ... of a $70 million Series E financing round. Participants ... and Sofinnova Ventures, and an undisclosed blue chip public ... F2 Capital, 7 Med Health Ventures, Abingworth and ARCH ...
(Date:2/26/2015)... , Feb. 27, 2015  Finesse expands office in ... Solutions announced the expansion of its operations in ... for mid-March and access for customers is expected shortly ... and located adjacent to the current office, the new ... engineering team and allow Finesse to bring on more ...
(Date:2/26/2015)... , Feb. 26, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ Insulin ... offering of 5,250,000 shares of its common stock at ... The net proceeds to Tandem from this offering are ... and commissions and other estimated offering expenses payable by ...
Breaking Medicine Technology:Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3New Finesse Office in United Kingdom 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3
... published in the American Journal of Nephrology -, ... announced that its Phase III data on VAPRISOL was ... Nephrology. In this study,VAPRISOL showed a significant increase in ... life-threatening condition that,occurs when the body,s sodium level falls ...
... Cancer patients at Beaumont,Hospitals are the first in the ... therapy that is painless, faster, more accurate and precise,than ... patented the new,technology, Omnibeam(R). The $3.3-million machine is manufactured ... first patient,was treated on Sept. 10. The painless ...
Cached Medicine Technology:Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 2Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 3Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 4Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia 5Beaumont Patients 1st to get Next Generation of Radiation Treatment 2
(Date:2/27/2015)... (PRWEB) February 27, 2015 According to ... in the China Dental Industry in 2013 rose by ... the total amount of revenue generated by the industry ... that was registered by the industry in 2013. ... The report has identified the oral industry as a ...
(Date:2/27/2015)... 2015 Several studies showing the promise ... have made headline news recently. However, all these studies ... in this month’s STEM CELLS Translational Medicine shows that ... children with congenital heart diseases that can lead to ... at the Mayo Clinic in Rochester, Minn., looked at ...
(Date:2/27/2015)... 2015 Ticket Down announces that Ed ... summer months of 2015. Tickets for his tour have ... at a record pace. , Ed Sheeran 2015 ... Erwin Center, Wednesday, May 6, 2015 , 5/7/15, Ed Sheeran ... May 7, 2015 , 5/9/15, Ed Sheeran Tickets, Tulsa, OK ...
(Date:2/27/2015)... 27, 2015 Burien Nursing and ... Health Care, Inc. with the Facility of the ... four key areas: Outstanding quality of care / satisfaction, ... Lynda Baldwin was invited to attend the awards banquet ... “I am delighted to receive this award on behalf ...
(Date:2/27/2015)... RDI-Engineering will be hosting an educational ... on March 14, at Moreno Valley College. The station ... to use engineering software and tools, and a few ... Moreno Valley College’s Upward Bound Math and Science (UBMS) ... hopes to encourage students to seek educational and career ...
Breaking Medicine News(10 mins):Health News:China Dental Industry to Expand Rapidly Owing to the Evolution of Medical and Healthcare Systems: MarketResearchReports.Biz 2Health News:China Dental Industry to Expand Rapidly Owing to the Evolution of Medical and Healthcare Systems: MarketResearchReports.Biz 3Health News:Study Shows Stem Cells Have Potential to Help Kids’ Hearts, Too 2Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 2Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 3Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 4Health News:Burien Nursing and Rehabilitation Center Receives Top Honors with Facility of the Year Award 2Health News:Burien Nursing and Rehabilitation Center Receives Top Honors with Facility of the Year Award 3Health News:RDI-Engineering Participates in STEM”U”LATE Your Mind Event to Host Educational Exhibition 2
... , NASHVILLE, Tenn. , Jan. 26 ... announced that on Monday evening, February 22, 2010 , after ... of 2009.   , On February 23, 2010 , at ... a conference call to discuss earnings results, quarterly activities, general operations ...
... , , OAKLAND, Calif. , ... union election results for Kaiser Permanente nurses, psych-social ... Trossman , communications director of the Service Employees ... statement: , "While today,s election results are disappointing, ...
... Jan. 26 Yesterday, Randall Terry , who is regrettably ... news release, "We are not coming to condone or condemn Scott ... figure John Brown . , The Advisory Board of Operation Rescue ... violence. , "The Board of Operation Rescue wants to make it clear ...
... CLEVELAND , Jan. 26 The Cleveland ... will host a panel discussion Feb. 18 addressing ... http://www.newscom.com/cgi-bin/prnh/20070517/IABCLOGO ) , Health care communication leaders from ... care reform, public option, social media and more are impacting ...
... , BALTIMORE , Jan. 26 Lutheran World ... has arrived safely. , "Our partners at Church World Service ... immediately to the people who need it," says Trevor Knoblich ... jointly by LWR and CWS, contained health kits and layettes from ...
... , COLUMBUS, Ohio , Jan. 26 ... of Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 30mL and 120mL ... and Drug Administration. This product is indicated for the relief of ... opioid analgesic is appropriate. , Roxane Laboratories, Inc. Morphine Sulfate Oral ...
Cached Medicine News:Health News:Healthcare Realty Trust Announces Fourth Quarter Earnings Release Date and Conference Call 2Health News:SEIU-UHW Statement on Kaiser Union Election in Southern California 2Health News:Operation Rescue's Advisory Board Issues Statement on Mr. Terry's Extremism 2Health News:IABC Cleveland Presents 'The Changing Face of Health Care Communications' at Feb. 18 Luncheon 2Health News:LWR Health Kits, Layettes Arrive in Haiti as Relief Efforts Ramp Up 2Health News:LWR Health Kits, Layettes Arrive in Haiti as Relief Efforts Ramp Up 3Health News:Roxane Laboratories, Inc. Announces the New Drug Application Approval of Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 2Health News:Roxane Laboratories, Inc. Announces the New Drug Application Approval of Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 3
Flexible rake retractor, 3 blunt prongs....
Rees bayonet forceps, standard, 5-1/2", TC....
... Implants, designed to accept rigid ... with an excellent reconstructive option ... floor blowout defects. Each design ... of one or more rigid ...
... Medpor Midface Rim is designed ... concavities of the midface, including ... malar. When positioned in the ... Medpor Midface Rim implant aids ...
Medicine Products: